PL2655378T3 - Związki i ich zastosowanie jako inhibitorów bace - Google Patents

Związki i ich zastosowanie jako inhibitorów bace

Info

Publication number: PL2655378T3
Authority: PL; Poland
Prior art keywords: compounds; bace inhibitors; bace; inhibitors
Prior art date: 2010-12-22

Application number

PL11850232T

Other languages

English (en)

Inventor

Gabor Csjernyik

Sofia Karlström

Annika Kers

Karin Kolmodin

Martin Nylöf

Liselotte Öhberg

Laszlo Rakos

Lars Sandberg

Fernando Sehgelmeble

Peter Söderman

Britt-Marie Swahn

Berg Stefan Von

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-22

Filing date

2011-12-21

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2655378(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2017-09-29 Publication of PL2655378T3 publication Critical patent/PL2655378T3/pl

Links

101150058765 BACE1 gene Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)

PL11850232T 2010-12-22 2011-12-21 Związki i ich zastosowanie jako inhibitorów bace PL2655378T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201061425852P	2010-12-22	2010-12-22
US201161529620P	2011-08-31	2011-08-31

Publications (1)

Publication Number	Publication Date
PL2655378T3 true PL2655378T3 (pl)	2017-09-29

Family

ID=46314249

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11850232T PL2655378T3 (pl)	2010-12-22	2011-12-21	Związki i ich zastosowanie jako inhibitorów bace

Country Status (40)

Country	Link
US (6)	US8415483B2 (pl)
EP (2)	EP2655378B1 (pl)
JP (3)	JP6180325B2 (pl)
KR (1)	KR101916975B1 (pl)
CN (2)	CN103380133B (pl)
AR (1)	AR084553A1 (pl)
AU (3)	AU2011345389B2 (pl)
BR (1)	BR112013016030B1 (pl)
CA (1)	CA2822378C (pl)
CL (1)	CL2013001849A1 (pl)
CO (1)	CO6781485A2 (pl)
CR (1)	CR20130308A (pl)
CY (1)	CY1119211T1 (pl)
DK (1)	DK2655378T3 (pl)
DO (3)	DOP2013000147A (pl)
EA (2)	EA032687B1 (pl)
EC (1)	ECSP13012708A (pl)
ES (2)	ES2780928T3 (pl)
GT (1)	GT201300165A (pl)
HR (1)	HRP20170723T1 (pl)
HU (1)	HUE033274T2 (pl)
LT (1)	LT2655378T (pl)
ME (1)	ME02728B (pl)
MX (1)	MX342477B (pl)
MY (1)	MY178156A (pl)
NI (1)	NI201300055A (pl)
NZ (2)	NZ709235A (pl)
PE (2)	PE20141191A1 (pl)
PH (2)	PH12017500851A1 (pl)
PL (1)	PL2655378T3 (pl)
PT (1)	PT2655378T (pl)
RS (1)	RS55961B1 (pl)
SA (2)	SA114360153B1 (pl)
SG (2)	SG191127A1 (pl)
SI (1)	SI2655378T1 (pl)
SM (1)	SMT201700243T1 (pl)
TW (2)	TWI618700B (pl)
UY (1)	UY33829A (pl)
WO (1)	WO2012087237A1 (pl)
ZA (1)	ZA201305495B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102812005B (zh)	2010-02-24	2014-12-10	生命医药公司	β-分泌酶抑制剂
US8415483B2 (en) *	2010-12-22	2013-04-09	Astrazeneca Ab	Compounds and their use as BACE inhibitors
EP2780321B1 (en)	2011-10-10	2015-12-30	Astrazeneca AB	Mono-fluoro beta-secretase inhibitors
US8779355B2 (en) *	2011-12-28	2014-07-15	Quest Diagnostics Investments, Inc.	Methods for detecting lacosamide by mass spectrometry
UA113538C2 (xx)	2012-01-26	2017-02-10		Фторметил-5,6-дигідро-4h-$1,3]оксазини
TWI557112B (zh) *	2012-03-05	2016-11-11	百靈佳殷格翰國際股份有限公司	β－分泌酶抑制劑
JP2015518048A (ja)	2012-05-30	2015-06-25	コメンティス，インコーポレイテッド	クロマン化合物
US9000182B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	Cycloalkyl ether compounds and their use as BACE inhibitors
US10548882B2 (en) *	2012-06-21	2020-02-04	Astrazeneca Ab	Camsylate salt
TW201422592A (zh)	2012-08-27	2014-06-16	Boehringer Ingelheim Int	β－分泌酶抑制劑
JP2015532282A (ja) *	2012-09-28	2015-11-09	ヴァイティーファーマシューティカルズ，インコーポレイテッド	β−セクレターゼの阻害剤
US20140371283A1 (en)	2013-02-12	2014-12-18	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
TW201629025A (zh)	2014-10-07	2016-08-16	阿斯特捷利康公司	化合物及其作為ｂａｃｅ抑制劑之用途
US20190262327A1 (en)	2016-03-15	2019-08-29	Astrazeneca Ab	Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
AR107783A1 (es)	2016-03-15	2018-06-06	Lilly Co Eli	Terapia de combinación
WO2017169503A1 (ja) *	2016-04-01	2017-10-05	国立大学法人千葉大学	含窒素芳香族アミドの製造方法、ピロール・イミダゾールポリアミドの製造方法、及び化合物
CN107892697B (zh)	2016-12-26	2020-11-03	郑州泰基鸿诺医药股份有限公司	一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN107954927A (zh) *	2017-10-30	2018-04-24	广东莱佛士制药技术有限公司	一种3-溴-5-(丙炔-1-基)吡啶的制备方法
WO2019122268A1 (en)	2017-12-21	2019-06-27	Astrazeneca Ab	Processes for the stereoselective preparation of bace inhibitors
WO2019122421A1 (en)	2017-12-22	2019-06-27	Astrazeneca Ab	Stereoselective ketone reduction using a ketoreductase enzyme
WO2019129750A1 (en)	2017-12-29	2019-07-04	Astrazeneca Ab	Processes for the racemization of dihydroimidazole ring systems
WO2019129755A1 (en)	2017-12-29	2019-07-04	Astrazeneca Ab	Ketal hydrogenation
CN110615751B (zh) *	2018-06-19	2021-08-17	上海医药工业研究院	一种2-氧代硫代丙酰胺的制备方法
JP2022525157A (ja)	2019-03-14	2022-05-11	アストラゼネカ・アクチエボラーグ	体重減少のためのラナベセスタット
CN111253427A (zh) *	2020-03-13	2020-06-09	苏州大学	正丁基锂在催化醛和硅烷的氰硅化反应中的应用
CN114989103B (zh) *	2022-06-09	2024-07-09	杭州科巢生物科技有限公司	一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100452491B1 (ko)	2001-03-29	2004-10-12	한미약품 주식회사	신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (en) *	2001-06-01	2002-12-12	Ono Pharmaceutical Co., Ltd.	Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7915424B2 (en)	2004-03-22	2011-03-29	Eli Lilly And Company	Pyridyl derivatives and their use as mGlu5 antagonists
MX2007016180A (es)	2005-06-14	2008-03-07	Schering Corp	Inhibidores de aspartil proteasas.
JP2009520686A (ja)	2005-11-21	2009-05-28	アストラゼネカ・アクチエボラーグ	新規な２−アミノ−イミダゾール−４−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用
CA2633992A1 (en)	2005-12-21	2007-07-05	Boehringer Ingelheim International Gmbh	Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en)	2006-02-24	2007-09-07	Wyeth	DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
CN101506162B (zh) *	2006-06-22	2012-06-27	阿斯利康(瑞典)有限公司	作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途
WO2008076044A1 (en) *	2006-12-20	2008-06-26	Astrazeneca Ab	Novel 2-amino-5, 5-diaryl-imidazol-4-ones
EP2108018A2 (en) *	2007-02-01	2009-10-14	Glaxo Group Limited	8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
AU2008248129B8 (en) *	2007-05-07	2013-05-30	Merck Sharp & Dohme Corp.	Gamma secretase modulators
WO2009100169A1 (en)	2008-02-06	2009-08-13	Glaxo Group Limited	Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr)	2008-04-15	2010-09-24	Inst Rech Developpement Ird	Sels de quinoleines 2-substituees
EP2318416B1 (en)	2008-07-28	2013-09-04	Eisai R&D Management Co., Ltd.	Spiroaminodihydrothiazine derivatives
US8450308B2 (en)	2008-08-19	2013-05-28	Vitae Pharmaceuticals, Inc.	Inhibitors of beta-secretase
CA2736130C (en)	2008-09-11	2014-01-14	Amgen Inc.	Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
CA2753730C (en) *	2009-03-13	2020-12-22	Vitae Pharmaceuticals, Inc.	Inhibitors of beta-secretase
TW201103893A (en)	2009-07-02	2011-02-01	Astrazeneca Ab	New compounds
TW201105650A (en)	2009-07-02	2011-02-16	Astrazeneca Ab	New compounds
CN102812005B (zh)	2010-02-24	2014-12-10	生命医药公司	β-分泌酶抑制剂
US20120065195A1 (en)	2010-03-31	2012-03-15	Clark Christopher T	Compounds for treating neurodegenerative diseases
WO2011130741A1 (en)	2010-04-16	2011-10-20	Array Biopharma Inc.	Compounds for treating neurodegenerative diseases
WO2012019056A1 (en)	2010-08-05	2012-02-09	Amgen Inc.	Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US20120083501A1 (en)	2010-09-24	2012-04-05	Hunt Kevin W	Compounds for treating neurodegenerative diseases
WO2012071458A1 (en)	2010-11-22	2012-05-31	Array Biopharma Inc.	Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US8415483B2 (en) *	2010-12-22	2013-04-09	Astrazeneca Ab	Compounds and their use as BACE inhibitors
EP2780321B1 (en)	2011-10-10	2015-12-30	Astrazeneca AB	Mono-fluoro beta-secretase inhibitors
US9000182B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en)	2012-06-20	2015-04-07	Astrazeneca Ab	Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) *	2012-06-20	2015-04-07	Astrazeneca Ab	Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en)	2012-06-21	2020-02-04	Astrazeneca Ab	Camsylate salt

2011
- 2011-12-20 US US13/331,284 patent/US8415483B2/en active Active
- 2011-12-21 SG SG2013045323A patent/SG191127A1/en unknown
- 2011-12-21 CA CA2822378A patent/CA2822378C/en active Active
- 2011-12-21 JP JP2013546075A patent/JP6180325B2/ja active Active
- 2011-12-21 SI SI201131195A patent/SI2655378T1/sl unknown
- 2011-12-21 RS RS20170483A patent/RS55961B1/sr unknown
- 2011-12-21 PT PT118502327T patent/PT2655378T/pt unknown
- 2011-12-21 TW TW100147843A patent/TWI618700B/zh not_active IP Right Cessation
- 2011-12-21 SM SM20170243T patent/SMT201700243T1/it unknown
- 2011-12-21 PH PH1/2017/500851A patent/PH12017500851A1/en unknown
- 2011-12-21 AU AU2011345389A patent/AU2011345389B2/en active Active
- 2011-12-21 CN CN201180068285.7A patent/CN103380133B/zh active Active
- 2011-12-21 EP EP11850232.7A patent/EP2655378B1/en active Active
- 2011-12-21 PE PE2013001452A patent/PE20141191A1/es active IP Right Grant
- 2011-12-21 HR HRP20170723TT patent/HRP20170723T1/hr unknown
- 2011-12-21 WO PCT/SE2011/051555 patent/WO2012087237A1/en not_active Ceased
- 2011-12-21 BR BR112013016030-6A patent/BR112013016030B1/pt active IP Right Grant
- 2011-12-21 HU HUE11850232A patent/HUE033274T2/en unknown
- 2011-12-21 EP EP17150757.7A patent/EP3176172B1/en active Active
- 2011-12-21 TW TW105141254A patent/TWI633092B/zh not_active IP Right Cessation
- 2011-12-21 EA EA201690787A patent/EA032687B1/ru not_active IP Right Cessation
- 2011-12-21 DK DK11850232.7T patent/DK2655378T3/en active
- 2011-12-21 KR KR1020137019193A patent/KR101916975B1/ko active Active
- 2011-12-21 NZ NZ709235A patent/NZ709235A/en not_active IP Right Cessation
- 2011-12-21 ME MEP-2017-115A patent/ME02728B/me unknown
- 2011-12-21 NZ NZ612041A patent/NZ612041A/en not_active IP Right Cessation
- 2011-12-21 PL PL11850232T patent/PL2655378T3/pl unknown
- 2011-12-21 EA EA201390830A patent/EA025746B9/ru not_active IP Right Cessation
- 2011-12-21 MX MX2013007319A patent/MX342477B/es active IP Right Grant
- 2011-12-21 CN CN201610341918.1A patent/CN106008355B/zh active Active
- 2011-12-21 SG SG10201602241SA patent/SG10201602241SA/en unknown
- 2011-12-21 MY MYPI2013701047A patent/MY178156A/en unknown
- 2011-12-21 PE PE2017001273A patent/PE20171342A1/es unknown
- 2011-12-21 ES ES17150757T patent/ES2780928T3/es active Active
- 2011-12-21 PH PH1/2013/501313A patent/PH12013501313A1/en unknown
- 2011-12-21 ES ES11850232.7T patent/ES2626727T3/es active Active
- 2011-12-21 LT LTEP11850232.7T patent/LT2655378T/lt unknown
- 2011-12-22 UY UY0001033829A patent/UY33829A/es not_active Application Discontinuation
- 2011-12-22 AR ARP110104899A patent/AR084553A1/es not_active Application Discontinuation
- 2011-12-24 SA SA114360153A patent/SA114360153B1/ar unknown
- 2011-12-24 SA SA111330107A patent/SA111330107B1/ar unknown
2013
- 2013-03-15 US US13/833,221 patent/US8865911B2/en active Active
- 2013-06-20 NI NI201300055A patent/NI201300055A/es unknown
- 2013-06-20 GT GT201300165A patent/GT201300165A/es unknown
- 2013-06-20 DO DO2013000147A patent/DOP2013000147A/es unknown
- 2013-06-21 CR CR20130308A patent/CR20130308A/es unknown
- 2013-06-21 CL CL2013001849A patent/CL2013001849A1/es unknown
- 2013-06-21 CO CO13148240A patent/CO6781485A2/es active IP Right Grant
- 2013-06-21 EC ECSP13012708 patent/ECSP13012708A/es unknown
- 2013-07-19 ZA ZA2013/05495A patent/ZA201305495B/en unknown
2014
- 2014-09-15 US US14/486,959 patent/US9248129B2/en not_active Expired - Fee Related
2015
- 2015-12-22 US US14/978,756 patent/US20160184303A1/en not_active Abandoned
2016
- 2016-01-29 AU AU2016200538A patent/AU2016200538B2/en not_active Ceased
- 2016-07-25 DO DO2016000191A patent/DOP2016000191A/es unknown
- 2016-07-29 JP JP2016149234A patent/JP6333317B2/ja active Active
2017
- 2017-01-31 DO DO2017000030A patent/DOP2017000030A/es unknown
- 2017-05-31 CY CY20171100566T patent/CY1119211T1/el unknown
- 2017-07-26 US US15/659,816 patent/US9918985B2/en not_active Expired - Fee Related
- 2017-11-14 AU AU2017261475A patent/AU2017261475A1/en not_active Abandoned
2018
- 2018-01-26 JP JP2018011088A patent/JP6527255B2/ja not_active Expired - Fee Related
- 2018-01-31 US US15/884,752 patent/US10231967B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW201716386A (zh)	2017-05-16
EP2655378A4 (en)	2014-07-09
DOP2016000191A (es)	2016-09-15
JP2014504300A (ja)	2014-02-20
US9918985B2 (en)	2018-03-20
EA032687B1 (ru)	2019-07-31
TW201302713A (zh)	2013-01-16
US20120165347A1 (en)	2012-06-28
SA114360153B1 (ar)	2015-11-29
TWI633092B (zh)	2018-08-21
AU2017261475A1 (en)	2017-11-30
SA111330107B1 (ar)	2015-03-26
US10231967B2 (en)	2019-03-19
SG191127A1 (en)	2013-07-31
PE20171342A1 (es)	2017-09-13
DOP2013000147A (es)	2013-10-15
US20150133471A1 (en)	2015-05-14
CN106008355A (zh)	2016-10-12
BR112013016030B1 (pt)	2022-03-29
PT2655378T (pt)	2017-05-29
ME02728B (me)	2017-10-20
JP6333317B2 (ja)	2018-05-30
PH12017500851A1 (en)	2023-08-14
EP2655378A1 (en)	2013-10-30
US20130210837A1 (en)	2013-08-15
CN106008355B (zh)	2019-05-03
KR20130143629A (ko)	2013-12-31
AU2011345389A1 (en)	2013-08-01
ZA201305495B (en)	2016-07-27
MX2013007319A (es)	2013-07-22
JP6180325B2 (ja)	2017-08-16
WO2012087237A1 (en)	2012-06-28
EP3176172B1 (en)	2020-01-29
US9248129B2 (en)	2016-02-02
AU2011345389B2 (en)	2015-10-29
DK2655378T3 (en)	2017-06-06
SMT201700243T1 (it)	2017-07-18
EA025746B1 (ru)	2017-01-30
EP2655378B1 (en)	2017-03-01
US20160184303A1 (en)	2016-06-30
US8865911B2 (en)	2014-10-21
HRP20170723T1 (hr)	2017-07-28
EA025746B9 (ru)	2017-06-30
ECSP13012708A (es)	2013-08-30
AR084553A1 (es)	2013-05-22
LT2655378T (lt)	2017-06-12
PH12013501313A1 (en)	2022-03-30
CA2822378A1 (en)	2012-06-28
CN103380133A (zh)	2013-10-30
MY178156A (en)	2020-10-06
TWI618700B (zh)	2018-03-21
CO6781485A2 (es)	2013-10-31
CN103380133B (zh)	2016-06-29
NZ709235A (en)	2016-11-25
EA201390830A1 (ru)	2013-12-30
CR20130308A (es)	2014-02-13
EA201690787A1 (ru)	2017-02-28
US20170319578A1 (en)	2017-11-09
CL2013001849A1 (es)	2013-12-20
JP2018083840A (ja)	2018-05-31
NZ612041A (en)	2015-07-31
JP2017008072A (ja)	2017-01-12
MX342477B (es)	2016-09-30
SG10201602241SA (en)	2016-04-28
ES2780928T3 (es)	2020-08-27
AU2016200538A1 (en)	2016-02-18
PE20141191A1 (es)	2014-09-21
UY33829A (es)	2012-07-31
RS55961B1 (sr)	2017-09-29
GT201300165A (es)	2015-02-11
EP3176172A1 (en)	2017-06-07
US20180221367A1 (en)	2018-08-09
AU2016200538B2 (en)	2017-08-31
KR101916975B1 (ko)	2018-11-08
CA2822378C (en)	2020-01-14
JP6527255B2 (ja)	2019-06-05
BR112013016030A2 (pt)	2018-07-24
US8415483B2 (en)	2013-04-09
ES2626727T3 (es)	2017-07-25
HUE033274T2 (en)	2017-11-28
NI201300055A (es)	2014-03-07
DOP2017000030A (es)	2017-02-28
SI2655378T1 (sl)	2017-06-30
CY1119211T1 (el)	2018-02-14

Publication	Publication Date	Title
ZA201305495B (en)	2016-07-27	Compounds and their use as bace inhibitors
IL246600B (en)	2018-10-31	Heterocyclic compounds and their use
IL222288A0 (en)	2012-12-31	Heterocyclic compounds and their uses
IL220939A0 (en)	2012-09-24	Compounds and methods
EP2523664A4 (en)	2013-06-26	COMPOUNDS AND METHODS
EP2637669A4 (en)	2014-04-02	Heterocyclic compounds and their use
PT2920149T (pt)	2019-07-23	Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos
IL222176B (en)	2018-05-31	Radioprotector compounds and methods
IL222227A0 (en)	2012-12-31	Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL220812A0 (en)	2012-08-30	Compounds and methods
PL2531518T3 (pl)	2017-01-31	Związki oligopeptydowe i ich zastosowania
GB201111705D0 (en)	2011-08-24	Compounds and their use
EP2523560A4 (en)	2013-07-03	CONNECTIONS AND METHODS
IL231082A (en)	2016-09-29	Pyrimido compounds - pyridazinone and their use
ZA201303773B (en)	2014-11-26	Compounds and their use
GB201114448D0 (en)	2011-10-05	Compounds and their use
GB201004450D0 (en)	2010-05-05	Compounds and methods relating thereto
GB201018028D0 (en)	2010-12-08	Compounds and their use
GB201000307D0 (en)	2010-02-24	Compounds and their use
GB201000305D0 (en)	2010-02-24	Compounds and their use
GB201000308D0 (en)	2010-02-24	Compounds and their use
GB201020848D0 (en)	2011-01-26	Compounds and their use
GB201000309D0 (en)	2010-02-24	Compounds and their use
GB201002337D0 (en)	2010-03-31	Compounds and their use
GB201017822D0 (en)	2010-12-01	Compounds and their use